(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of -24.86% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 88.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.64%.
Ptc Therapeutics's revenue in 2025 is $1,772,758,000.On average, 5 Wall Street analysts forecast PTCT's revenue for 2025 to be $136,927,279,277, with the lowest PTCT revenue forecast at $134,088,609,885, and the highest PTCT revenue forecast at $139,833,158,622. On average, 5 Wall Street analysts forecast PTCT's revenue for 2026 to be $69,842,553,255, with the lowest PTCT revenue forecast at $57,707,035,534, and the highest PTCT revenue forecast at $83,021,727,403.
In 2027, PTCT is forecast to generate $78,543,151,030 in revenue, with the lowest revenue forecast at $65,727,845,857 and the highest revenue forecast at $93,609,672,571.